Nutritional Impact of Orkambi Treatment in 2 to 5 Year Old Children Homozygous for F508del Mutations
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 04 Jan 2019 Status changed from planning to recruiting.
- 04 May 2018 New trial record
- 26 Apr 2018 According to a Vertex Pharmaceuticals media release, this trial is anticipated to start in the second half of 2018.